Thomas Riga has served as our Chief Operating Officer since December 2017, as Executive Vice President, Chief Operating Officer & Head of Business Development since May 2017 and as our Senior Vice President & Chief Commercial Officer since August 2014. From July 2013 to August 2014, he served as our Vice President, Corporate Accounts. During his tenure as Chief Operating Officer, Mr. Riga has led Spectrum’s focus from a specialty pharmaceutical company to a development-focused organization. The divestiture of seven marketed products infused non-dilutive capital back into the organization and enabled Spectrum to further advance its two cornerstone, value driving assets. As Chief Commercial Officer, he led multiple product launches in the oncology market, delivering innovative cancer care while establishing world class partnerships with key industry stakeholders. He has consistently inspired cross-functional teams to deliver superior performance to create value for Spectrum and optimized the commercial organization to advance our competitive advantage.
Mr. Riga has over 20 years of pharmaceutical leadership experience. He has management experience in various positions at Wyeth Ayerst Pharmaceuticals, Eli Lilly and Company, Amgen Inc. and Dendreon Pharmaceuticals LLC. Throughout his career he has successfully integrated leadership and strategy to create meaningful value. His executive leadership experience spans across operations, business development, sales, marketing, Six Sigma (black belt), manufacturing, and corporate accounts. Mr. Riga is an accredited public company director from UCLA’s Anderson School of Business.
Mr. Riga holds a bachelor’s degree in Biology and Chemistry from St. Lawrence University, Canton, New York.
What is Thomas J. Riga's net worth?
The estimated net worth of Thomas J. Riga is at least $408,726.45 as of March 14th, 2023. Mr. Riga owns 503,792 shares of Spectrum Pharmaceuticals stock worth more than $408,726 as of March 21st. This net worth estimate does not reflect any other assets that Mr. Riga may own. Learn More about Thomas J. Riga's net worth.
What is Thomas J. Riga's salary?
As the COO of Spectrum Pharmaceuticals, Inc., Mr. Riga earned a total compensation package of $2,788,857.00 in 2021. Mr. Riga earned a salary of $550,000.00, a bonus of $364,000.00, stock awards of $478,500.00, options awards of $1,290,829.00, and other compensation of $105,528.00. Learn More on Thomas J. Riga's salary.
How do I contact Thomas J. Riga?
Has Thomas J. Riga been buying or selling shares of Spectrum Pharmaceuticals?
During the past quarter, Thomas J. Riga has sold $89,945.47 of Spectrum Pharmaceuticals stock. Most recently, Thomas J. Riga sold 18,153 shares of the business's stock in a transaction on Tuesday, March 14th. The shares were sold at an average price of $0.82, for a transaction totalling $14,885.46. Following the completion of the sale, the chief executive officer now directly owns 503,792 shares of the company's stock, valued at $413,109.44. Learn More on Thomas J. Riga's trading history.
Who are Spectrum Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Spectrum Pharmaceuticals?
During the last twelve months, Spectrum Pharmaceuticals insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $22,500.00. During the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 218,922 shares worth more than $139,969.16. The most recent insider tranaction occured on March, 14th when insider Keith M Mcgahan sold 15,733 shares worth more than $12,901.06. Insiders at Spectrum Pharmaceuticals own 2.7% of the company.
Learn More about insider trades at Spectrum Pharmaceuticals. Information on this page was last updated on 3/14/2023.
